Co-Diagnostics Receives CE Mark for Tuberculosis Test Kit
The CE mark confirms that the test meets the Essential Requirements of the European Community’s In-Vitro Diagnostic Medical Device Directive (IVDD 98/79/EC). The Logix Smart MTB Test detects DNA of mycobacteria tuberculosis (MTB) complex members and functions via real-time polymerase chain reaction (PCR) to detect and amplify the IS6110 and MPB64 regions of the MTB genome.
About
Forward-Looking Statements:
This press release contains forward-looking statements.Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.Readers of this press release are cautioned not to place undue reliance on any forward-looking statements.The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180725005242/en/
Source:
Company Contact:
Co-Diagnostics, Inc.
Andrew Benson
Co-Diagnostics
Investor Relations
801-438-1036
investors@codiagnostics.com
or
Investor
Contact:
Lytham Partners, LLC
Joe Diaz, Robert Blum and
Joe Dorame
602-889-9700
codx@lythampartners.com